Scarica l'app Stockscreener
134.75
0.00%
0.00
Precedente Chiudi:
$134.75
Aprire:
$134.79
Volume 24 ore:
948.28K
Relative Volume:
0.36
Capitalizzazione di mercato:
$10.20B
Reddito:
-
Utile/perdita netta:
$-274.62M
Rapporto P/E:
-31.14
EPS:
-4.3278
Flusso di cassa netto:
$-235.37M
1 W Prestazione:
+0.15%
1M Prestazione:
+0.41%
6M Prestazione:
+97.03%
1 anno Prestazione:
+270.70%
Intervallo 1D:
$134.70
$134.82
Intervallo di 1 settimana:
$134.51
$134.88
Portata 52W:
$35.39
$134.88
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
134.75 | 10.20B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Hold |
| 2026-01-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Iniziato | Wolfe Research | Peer Perform |
| 2025-12-17 | Iniziato | Stephens | Overweight |
| 2025-12-10 | Iniziato | Deutsche Bank | Buy |
| 2025-11-03 | Iniziato | Craig Hallum | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-07 | Reiterato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
Apogee Therapeutics Market Sentiment - Benzinga España
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - news.stocktradersdaily.com
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat
APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal By Investing.com - Investing.com South Africa
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com Nigeria
APOGEE THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan
Apogee Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Apogee Therapeutics,Q2 2026 Net Loss $85.9 - Moomoo
My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale
Apogee Therapeutics, Inc. (APGE): An Insightful Stock Analysis on Growth Potential and Market Position - DirectorsTalk Interviews
APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingView
Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeat
Apogee Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss - marketscreener.com
Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative
Apogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - The Manila Times
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE - MarketBeat
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares By Investing.com - Investing.com India
Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common shares - Bitget
Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan - Stock Titan
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits all-time high at 134.47 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits all-time high at 134.47 USD - Investing.com
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):